Trade Castle Biosciences, Inc. - CSTL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.37 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 19.63 |
| Open | 19.59 |
| 1-Year Change | -2% |
| Day's Range | 19.36 - 19.92 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 14, 2025 | 19.75 | 0.16 | 0.82% | 19.59 | 20.01 | 19.36 |
| Apr 11, 2025 | 19.63 | 0.50 | 2.61% | 19.13 | 19.70 | 18.79 |
| Apr 10, 2025 | 19.24 | 0.39 | 2.07% | 18.85 | 19.65 | 18.27 |
| Apr 9, 2025 | 19.96 | 2.05 | 11.45% | 17.91 | 20.53 | 17.91 |
| Apr 8, 2025 | 18.47 | -0.81 | -4.20% | 19.28 | 20.00 | 18.10 |
| Apr 7, 2025 | 18.28 | 0.80 | 4.58% | 17.48 | 19.78 | 17.24 |
| Apr 4, 2025 | 18.42 | 0.12 | 0.66% | 18.30 | 18.71 | 17.58 |
| Apr 3, 2025 | 19.08 | 0.40 | 2.14% | 18.68 | 19.18 | 18.52 |
| Apr 2, 2025 | 20.12 | 0.87 | 4.52% | 19.25 | 20.29 | 19.12 |
| Apr 1, 2025 | 19.61 | 0.58 | 3.05% | 19.03 | 20.14 | 19.03 |
| Mar 31, 2025 | 19.84 | 0.81 | 4.26% | 19.03 | 20.24 | 18.94 |
| Mar 28, 2025 | 19.75 | -0.08 | -0.40% | 19.83 | 19.89 | 19.51 |
| Mar 27, 2025 | 19.92 | -0.04 | -0.20% | 19.96 | 20.27 | 19.70 |
| Mar 26, 2025 | 19.96 | -0.63 | -3.06% | 20.59 | 20.65 | 19.88 |
| Mar 25, 2025 | 20.67 | -0.18 | -0.86% | 20.85 | 20.85 | 20.36 |
| Mar 24, 2025 | 20.81 | 0.41 | 2.01% | 20.40 | 20.96 | 20.37 |
| Mar 21, 2025 | 20.45 | 1.01 | 5.20% | 19.44 | 20.93 | 19.44 |
| Mar 20, 2025 | 19.99 | 0.02 | 0.10% | 19.97 | 20.43 | 19.83 |
| Mar 19, 2025 | 20.42 | 0.42 | 2.10% | 20.00 | 20.63 | 19.75 |
| Mar 18, 2025 | 20.34 | 0.90 | 4.63% | 19.44 | 20.48 | 19.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Castle Biosciences Inc. Company profile
About Castle Biosciences Inc
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP) test. It developed and market DecisionDx-Melanoma to healthcare providers for use with patients diagnosed with invasive cutaneous melanoma. It developed DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. It developed DecisionDx DiffDx-Melanoma, a GEP test designed to be used as an adjunct to histopathology when the distinction between a benign lesion and melanoma is uncertain.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Castle Biosciences Inc revenues increased 50% to $94.1M. Net loss increased from $10.3M to $31.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, General and Administrative. increase of 68% to $70.9M (expense), Research & Development - Balancing value increase from $11.7M to $24.9M (expense).
| Industry: | Laboratory Diagnostic & Testing Substances |
505 S Friendswood Drive
2014 San Miguel Dr
FRIENDSWOOD
TEXAS 77546
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com